Silver Nanoparticles for the Therapy of Tuberculosis

References

• Thoen CO, LoBue PA, Enarson DA, Kaneene JB, de Kantor IN. Tuberculosis: a re-emerging disease in animals and humans. Vet Ital. 2009;45(1):135–181.20391396
   PubMed Web of Science ®Google Scholar
• De Lorenzo S, Tiberi S. Tuberculosis a re-emerging disease. Intern Emerg Med. 2012;7(S3):185–187. doi:10.1007/s11739-012-0822-9
   Google Scholar
• World Health Organization. Global Tuberculosis Report 2015, 20th Ed. World Health Organization; 2015.
   Google Scholar
• Schneider E, Moore M, Castro KG. Epidemiology of Tuberculosis in the United States. Clin Chest Med. 2005;26(2):183–195. doi:10.1016/j.ccm.2005.02.00715837104
   PubMed Web of Science ®Google Scholar
• Forrellad MA, Klepp LI, Gioffré A, et al. Virulence factors of the Mycobacterium tuberculosis complex. Virulence. 2013;4(1):3–66. doi:10.4161/viru.2232923076359
   PubMed Web of Science ®Google Scholar
• who.tb.99.260.pdf. Available from: https://www.who.int/docstore/gtb/publications/mdrtb/PDF/who.tb.99.260.pdf. Accessed 1121, 2019.
   Google Scholar
• 9789241565714-eng.pdf. Available from: https://apps.who.int/iris/bitstream/handle/10665/329368/9789241565714-eng.pdf. Accessed 1124, 2019..
   Google Scholar
• Saravanan M, Niguse S, Abdulkader M, et al. Review on emergence of drug-resistant tuberculosis (MDR & XDR-TB) and its molecular diagnosis in Ethiopia. Microb Pathog. 2018;117:237–242. doi:10.1016/j.micpath.2018.02.04729486274
   PubMed Web of Science ®Google Scholar
• Richter E, Weizenegger M, Rüsch-gerdes S, Niemann S. Evaluation of genotype MTBC assay for differentiation of clinical Mycobacterium tuberculosis complex isolates. J Clin Microbiol. 2003;41(6):2672–2675. doi:10.1128/JCM.41.6.2672-2675.200312791901
   PubMed Web of Science ®Google Scholar
• Thoen CO, Steele JH, Kaneene JB. Zoonotic Tuberculosis: Mycobacterium Bovis and Other Pathogenic Mycobacteria. John Wiley & Sons; 2014.
   Google Scholar
• Kiers A, Klarenbeek A, Mendelts B, Van Soolingen D, Koëter G. Transmission of Mycobacterium pinnipedii to humans in a zoo with marine mammals. Int J Tuberc Lung Dis off J Int Union Tuberc Lung Dis. 2008;12(12):1469–1473.
   PubMed Web of Science ®Google Scholar
• Alexander KA, Laver PN, Michel AL, et al. Novel Mycobacterium tuberculosis complex pathogen, M. mungi. Emerg Infect Dis. 2010;16(8):1296–1299. doi:10.3201/eid1608.10031420678329
   PubMed Web of Science ®Google Scholar
• Sathiyavimal S, Vasantharaj S, Bharathi D, et al. Biogenesis of copper oxide nanoparticles (CuONPs) using Sida acuta and their incorporation over cotton fabrics to prevent the pathogenicity of Gram negative and Gram positive bacteria. J Photochem Photobiol B. 2018;188:126–134. doi:10.1016/j.jphotobiol.2018.09.01430267962
   PubMed Web of Science ®Google Scholar
• Shankar PD, Shobana S, Karuppusamy I, et al. A review on the biosynthesis of metallic nanoparticles (gold and silver) using bio-components of microalgae: formation mechanism and applications. Enzyme Microb Technol. 2016;95:28–44. doi:10.1016/j.enzmictec.2016.10.01527866624
   PubMed Web of Science ®Google Scholar
• Silvestry-Rodriguez N, Sicairos-Ruelas EE, Gerba CP, Bright KR. Silver as a Disinfectant In: Ware GW, editor. Reviews of Environmental Contamination and Toxicology. Vol. 191 New York: Springer New York; 2007:23–45. doi:10.1007/978-0-387-69163-3_217708071
   PubMedGoogle Scholar
• Paladini F, Pollini M. Antimicrobial silver nanoparticles for wound healing application: progress and future trends. Materials. 2019;12(16):2540. doi:10.3390/ma12162540
   PubMed Web of Science ®Google Scholar
• Shanmuganathan R, Karuppusamy I, Saravanan M, Muthukumar H, Ponnuchamy K, Pugazhendhi VSR. Synthesis of silver nanoparticles and their biomedical applications - a comprehensive review. Current Pharmaceut Design2019. doi: 10.2174/1381612825666190708185506
   PubMed Web of Science ®Google Scholar
• Sakamoto K. The pathology of Mycobacterium tuberculosis infection. Vet Pathol. 2012;49(3):423–439. doi:10.1177/030098581142931322262351
   PubMed Web of Science ®Google Scholar
• Mohanty S, Jena P, Mehta R, et al. Cationic antimicrobial peptides and biogenic silver nanoparticles kill mycobacteria without eliciting DNA damage and cytotoxicity in mouse macrophages. Antimicrob Agents Chemother. 2013;57(8):3688–3698. doi:10.1128/AAC.02475-1223689720
   PubMed Web of Science ®Google Scholar
• Montelongo-Peralta LZ, León-Buitimea A, Palma-Nicolás JP, Gonzalez-Christen J, Morones-Ramírez JR. Antibacterial activity of combinatorial treatments composed of transition-metal/antibiotics against Mycobacterium tuberculosis. Sci Rep. 2019;9(1):1–6. doi:10.1038/s41598-019-42049-530626917
   PubMedGoogle Scholar
• Maher D, Raviglione M. Global epidemiology of tuberculosis. Clin Chest Med. 2005;26(2):167–182. doi:10.1016/j.ccm.2005.02.00915837103
   PubMed Web of Science ®Google Scholar
• Seung et al. 2015 Multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis.pdf. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4561400/pdf/cshperspectmed-TUB-a017863.pdf. Accessed 1124, 2019.
   Google Scholar
• Seung KJ, Keshavjee S, Rich ML. Multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis. Cold Spring Harb Perspect Med. 2015;5:9. doi:10.1101/cshperspect.a017863
   Web of Science ®Google Scholar
• World Health Organization 2007 - Global tuberculosis control surveillance, plannin.pdf. Available from: https://apps.who.int/iris/bitstream/handle/10665/144567/9241563141_eng.pdf?sequence=1. Accessed 1124, 2019.
   Google Scholar
• Chung-Delgado K, Guillen-Bravo S, Revilla-Montag A, Bernabe-Ortiz A. Mortality among MDR-TB cases: comparison with drug-susceptible tuberculosis and associated factors. PLoS One. 2015;10:3. doi:10/f7b7v6
   Web of Science ®Google Scholar
• Shin SS, Furin JJ, Alcántara F, Bayona J, Sánchez E, Mitnick CD. Long-term follow-up for multidrug-resistant tuberculosis. Emerg Infect Dis. 2006;12(4):687–688. doi:10.3201/eid1204.04125616704823
   PubMed Web of Science ®Google Scholar
• Bernabé-Ortiz A. Factores asociados a supervivencia en pacientes con tuberculosis en Lima, Perú [Factors associated with survival of patients with tuberculosis in Lima, Peru]. Rev Chil Infectologia Organo of Soc Chil Infectologia. 2008;25(2):104–107. Spanish.
   PubMed Web of Science ®Google Scholar
• Ginsberg AM, Spigelman M. Challenges in tuberculosis drug research and development. Nat Med. 2007;13(3):290–294. doi:10.1038/nm0307-29017342142
   PubMed Web of Science ®Google Scholar
• Takiff H, Guerrero E. Current prospects for the fluoroquinolones as first-line tuberculosis therapy. Antimicrob Agents Chemother. 2011;55(12):5421–5429. doi:10.1128/AAC.00695-1121876059
   PubMed Web of Science ®Google Scholar
• Ramachandran G, Swaminathan S. Safety and tolerability profile of second-line anti-tuberculosis medications. Drug Saf. 2015;38(3):253–269. doi:10.1007/s40264-015-0267-y25676682
   PubMed Web of Science ®Google Scholar
• Marra F, Marra CA, Bruchet N, et al. Adverse drug reactions associated with first-line anti-tuberculosis drug regimens. Available from: https://www.ingentaconnect.com/content/iuatld/ijtld/2007/00000011/00000008/art00007. 8 2007 Accessed 122, 2019.
   Google Scholar
• Natarajan S, Subramanian P. Adverse drug reactions to second line anti tuberculosis drugs: a prospective study in Mumbai, India. Eur Respir J. 2013;42(Suppl57).
   Google Scholar
• Sotgiu G, Centis R, D’ambrosio L, Migliori GB. Tuberculosis treatment and drug regimens. Cold Spring Harb Perspect Med. 2015;5(5):a017822–a017822. doi:10.1101/cshperspect.a01782225573773
   PubMed Web of Science ®Google Scholar
• Crofton SJ, Chaulet P, Maher D, et al. Guidelines for the Management of Drug-Resistant Tuberculosis. Vol No. WHO/TB/96.210 (Rev. 1). Geneva: World Health Organization; 1997.
   Google Scholar
• O’Brien RJ, Spigelman M. New drugs for tuberculosis: current status and future prospects. Clin Chest Med. 2005;26(2):327–340. doi:10.1016/j.ccm.2005.02.01315837114
   PubMed Web of Science ®Google Scholar
• Ernst JD. Macrophage receptors for Mycobacterium tuberculosis. Infect Immun. 1998;66(4):1277–1281. doi:10.1128/IAI.66.4.1277-1281.19989529042
   PubMed Web of Science ®Google Scholar
• Porvaznik I, Solovič I, Mokrý J. Non-tuberculous mycobacteria: classification, diagnostics, and therapy. Adv Exp Med Biol. 2017;944:19–25. doi:10.1007/978-3-319-44488-8_4527826888
   PubMed Web of Science ®Google Scholar
• Azadi D, Motallebirad T, Ghaffari K, Shojaei H. Mycobacteriosis and tuberculosis: laboratory diagnosis. Open Microbiol J. 2018;12:41–58. doi:10.2174/187428580181201004129785215
   PubMedGoogle Scholar
• Lesley R, Ramakrishnan L. Insights into early mycobacterial pathogenesis from the zebrafish. Curr Opin Microbiol. 2008;11(3):277–283. doi:10.1016/j.mib.2008.05.01318571973
   PubMed Web of Science ®Google Scholar
• Zachary JF, McGavin MD. Pathologic Basis of Veterinary Disease Expert Consult. Elsevier Health Sciences; 2016.
   Google Scholar
• Smith I. Mycobacterium tuberculosis pathogenesis and molecular determinants of virulence. Clin Microbiol Rev. 2003;16(3):463–496. doi:10.1128/CMR.16.3.463-496.200312857778
   PubMed Web of Science ®Google Scholar
• Echeverria-Valencia G, Flores-Villalva S, Espitia CI. Virulence factors and pathogenicity of Mycobacterium In: Ribón W editor. Mycobacterium - Research and Development. InTech; 2018:231–255. doi:10.5772/intechopen.72027
   Google Scholar
• Torrelles JB, Sieling PA, Zhang N, et al. Isolation of a distinct Mycobacterium tuberculosis mannose-capped lipoarabinomannan isoform responsible for recognition by CD1b-restricted T cells. Glycobiology. 2012;22(8):1118–1127. doi:10.1093/glycob/cws07822534567
   PubMed Web of Science ®Google Scholar
• Fratti RA, Chua J, Vergne I, Deretic V. Mycobacterium tuberculosis glycosylated phosphatidylinositol causes phagosome maturation arrest. Proc Natl Acad Sci. 2003;100(9):5437–5442. doi:10.1073/pnas.073761310012702770
   PubMed Web of Science ®Google Scholar
• Hmama Z. Quantitative analysis of phagolysosome fusion in intact cells: inhibition by mycobacterial lipoarabinomannan and rescue by an 1,25-dihydroxyvitamin D3-phosphoinositide 3-kinase pathway. J Cell Sci. 2004;117(10):2131–2140. doi:10.1242/jcs.0107215090599
   PubMed Web of Science ®Google Scholar
• Chan J, Xuedong F, Shirley WH, Patrick B, Bloom B. Lipoarabinomannan, a possible virulence factor involved in persistence of Mycobacterium tuberculosis within macrophages. Infect Immun. 1991;59(5):1755–1761. doi:10.1128/IAI.59.5.1755-1761.19911850379
   PubMed Web of Science ®Google Scholar
• Shabaana AK, Kulangara K, Semac I, et al. Mycobacterial lipoarabinomannans modulate cytokine production in human T helper cells by interfering with raft/microdomain signalling. CMLS Cell Mol Life Sci. 2005;62(2):179–187. doi:10.1007/s00018-004-4404-515666089
   PubMed Web of Science ®Google Scholar
• Geijtenbeek TBH, van Vliet SJ, Koppel EA, et al. Mycobacteria target DC-SIGN to suppress dendritic cell function. J Exp Med. 2003;197(1):7–17. doi:10.1084/jem.2002122912515809
   PubMed Web of Science ®Google Scholar
• Dao et al. 2004 Mycobacterium tuberculosis lipomannan induces apoptosis and interleukin-12.pdf. Available from: https://iai.asm.org/content/72/4/2067.full.pdf. Accessed 1122, 2019.
   Google Scholar
• Quesniaux VJ, Nicolle DM, Torres D, et al. Toll-Like Receptor 2 (TLR2)-dependent-positive and TLR2-independent-negative regulation of proinflammatory cytokines by mycobacterial lipomannans. J Immunol. 2004;172(7):4425–4434. doi:10.4049/jimmunol.172.7.442515034058
   PubMed Web of Science ®Google Scholar
• Indrigo J. Cord factor trehalose 6,6ʹ-dimycolate (TDM) mediates trafficking events during mycobacterial infection of murine macrophages. Microbiology. 2003;149(8):2049–2059. doi:10.1099/mic.0.26226-012904545
   PubMedGoogle Scholar
• Axelrod S, Oschkinat H, Enders J, et al. Delay of phagosome maturation by a mycobacterial lipid is reversed by nitric oxide. Cell Microbiol. 2008;10(7):1530–1545. doi:10.1111/j.1462-5822.2008.01147.x18363878
   PubMed Web of Science ®Google Scholar
• Welsh KJ, Abbott AN, Hwang S-A, et al. A role for tumour necrosis factor-, complement C5 and interleukin-6 in the initiation and development of the mycobacterial cord factor trehalose 6,6ʹ-dimycolate induced granulomatous response. Microbiology. 2008;154(6):1813–1824. doi:10.1099/mic.0.2008/016923-018524936
   PubMedGoogle Scholar
• Perez RL, Roman J, Roser S, et al. Cytokine message and protein expression during lung granuloma formation and resolution induced by the mycobacterial cord factor trehalose-6,6′-dimycolate. J Interferon Cytokine Res. 2000;20(9):795–804. doi:10.1089/1079990005015106711032399
   PubMed Web of Science ®Google Scholar
• Laneelle G, Tocanne J-F. Evidence for penetration in liposomes and in mitochondrial membranes of a fluorescent analogue of cord factor. Eur J Biochem. 1980;109(1):177–182. doi:10.1111/j.1432-1033.1980.tb04782.x7408875
   PubMedGoogle Scholar
• Kato M. Site II-specific inhibition of mitochondrial oxidative phosphorylation by trehalose-6,6′-dimycolate (cord factor) of Mycobacterium tuberculosis. Arch Biochem Biophys. 1970;140(2):379–390. doi:10.1016/0003-9861(70)90079-24319595
   PubMed Web of Science ®Google Scholar
• Ozeki Y, Kaneda K, Fujiwara N, Morimoto M, Oka S, Yano I. In vivo induction of apoptosis in the thymus by administration of mycobacterial cord factor (trehalose 6,6’-dimycolate).. Infect Immun. 1997;65(5):1793–1799. doi:10.1128/IAI.65.5.1793-1799.19979125563
   PubMed Web of Science ®Google Scholar
• Gilleron M, Ronet C, Mempel M, Monsarrat B, Gachelin G, Puzo G. Acylation state of the phosphatidylinositol mannosides from mycobacterium bovis bacillus calmette guérin and ability to induce granuloma and recruit natural killer T cells. J Biol Chem. 2001;276(37):34896–34904. doi:10.1074/jbc.M10390820011441009
   PubMed Web of Science ®Google Scholar
• Court N, Rose S, Bourigault M-L, et al. Mycobacterial PIMs inhibit host inflammatory responses through CD14-Dependent and CD14-Independent mechanisms. PLoS One. 2011;6(9):e24631. doi:10.1371/journal.pone.002463121949737
   PubMed Web of Science ®Google Scholar
• Cambier CJ, Takaki KK, Larson RP, et al. Mycobacteria manipulate macrophage recruitment through coordinated use of membrane lipids. Nature. 2014;505(7482):218–222. doi:10.1038/nature1279924336213
   PubMed Web of Science ®Google Scholar
• Rousseau C, Winter N, Pivert E, et al. Production of phthiocerol dimycocerosates protects Mycobacterium tuberculosis from the cidal activity of reactive nitrogen intermediates produced by macrophages and modulates the early immune response to infection. Cell Microbiol. 2004;6(3):277–287. doi:10.1046/j.1462-5822.2004.00368.x14764111
   PubMed Web of Science ®Google Scholar
• Astarie-Dequeker C, Le Guyader L, Malaga W, et al. Phthiocerol dimycocerosates of M. tuberculosis participate in macrophage invasion by inducing changes in the organization of plasma membrane lipids. PLoS Pathog. 2009;5(2):e1000289. doi:10.1371/journal.ppat.100028919197369
   PubMed Web of Science ®Google Scholar
• Augenstreich J, Arbues A, Simeone R, et al. ESX-1 and phthiocerol dimycocerosates of Mycobacterium tuberculosis act in concert to cause phagosomal rupture and host cell apoptosis. Cell Microbiol. 2017;19(7):e12726. doi:10.1111/cmi.12726
   Web of Science ®Google Scholar
• Saint-Joanis B, Demangel C, Jackson M, et al. Inactivation of Rv2525c, a substrate of the Twin Arginine Translocation (Tat) System of Mycobacterium tuberculosis, increases -lactam susceptibility and virulence. J Bacteriol. 2006;188(18):6669–6679. doi:10.1128/JB.00631-0616952959
   PubMed Web of Science ®Google Scholar
• Bhuwan M, Arora N, Sharma A, et al. Interaction of Mycobacterium tuberculosis virulence factor RipA with chaperone MoxR1 is required for transport through the TAT secretion system. mBio. 2016;7(2):e02259–15. doi:10.1128/mBio.02259-1526933057
   PubMed Web of Science ®Google Scholar
• Berthet F. Attenuation of virulence by disruption of the Mycobacterium tuberculosis erp Gene. Science. 1998;282(5389):759–762. doi:10.1126/science.282.5389.7599784137
   PubMed Web of Science ®Google Scholar
• Skjot RLV, Oettinger T, Rosenkrands I, et al. Comparative evaluation of low-molecular-mass proteins from mycobacterium tuberculosis identifies members of the ESAT-6 family as immunodominant T-cell antigens. Infect Immun. 2000;68(1):214–220. doi:10.1128/IAI.68.1.214-220.200010603390
   PubMed Web of Science ®Google Scholar
• Elhay MJ, Oettinger T, Andersen P. Delayed-type hypersensitivity responses to ESAT-6 and MPT64 from Mycobacterium tuberculosis in the Guinea Pig.:3. Infect Immun. 1998;66:3454–3456. doi:10.1128/IAI.66.7.3454-3456.19989632623
   PubMed Web of Science ®Google Scholar
• Ganguly N, Giang PH, Gupta C, et al. Mycobacterium tuberculosis secretory proteins CFP-10, ESAT-6 and the CFP10: ESAT6complex inhibit lipopolysaccharide-induced NF-κB transactivation by downregulation of reactive oxidative species (ROS) production. Immunol Cell Biol. 2008;86(1):98–106. doi:10.1038/sj.icb.710011717909563
   PubMed Web of Science ®Google Scholar
• Pathak SK, Basu S, Basu KK, et al. Direct extracellular interaction between the early secreted antigen ESAT-6 of Mycobacterium tuberculosis and TLR2 inhibits TLR signaling in macrophages. Nat Immunol. 2007;8(6):610–618. doi:10.1038/ni146817486091
   PubMed Web of Science ®Google Scholar
• Derrick SC, Morris SL. The ESAT6 protein of Mycobacterium tuberculosis induces apoptosis of macrophages by activating caspase expression. Cell Microbiol. 2007;9(6):1547–1555. doi:10.1111/j.1462-5822.2007.00892.x17298391
   PubMed Web of Science ®Google Scholar
• Smith J, Manoranjan J, Pan M, et al. Evidence for pore formation in host cell membranes by ESX-1-secreted ESAT-6 and its role in Mycobacterium marinum escape from the vacuole. Infect Immun. 2008;76(12):5478–5487. doi:10.1128/IAI.00614-0818852239
   PubMed Web of Science ®Google Scholar
• Kinhikar AG, Verma I, Chandra D, et al. Potential role for ESAT6 in dissemination of Maf tuberculosis via human lung epithelial cells. Mol Microbiol. 2010;75(1):92–106. doi:10.1111/j.1365-2958.2009.06959.x19906174
   PubMed Web of Science ®Google Scholar
• van der Wel N, Hava D, Houben D, et al. M. tuberculosis and M. leprae translocate from the phagolysosome to the cytosol in myeloid cells. Cell. 2007;129(7):1287–1298. doi:10.1016/j.cell.2007.05.05917604718
   PubMed Web of Science ®Google Scholar
• Reed MB, Domenech P, Manca C, et al. A glycolipid of hypervirulent tuberculosis strains that inhibits the innate immune response. Nature. 2004;431(7004):84–87. doi:10.1038/nature0283715343336
   PubMed Web of Science ®Google Scholar
• Alexander KA, Sanderson CE, Larsen MH, Robbe-austerman S, Williams MC, Palmer MV. Emerging tuberculosis pathogen hijacks social communication behavior in the group-living banded mongoose (Mungos mungo). mBio. 2016;7:3. doi:10.1128/mBio.00281-16
   Web of Science ®Google Scholar
• Henderson RA, Watkins SC, Flynn JL. Activation of human dendritic cells following infection with Mycobacterium tuberculosis. J Immunol. 1997;159(2):635–643.9218578
   PubMed Web of Science ®Google Scholar
• Ganbat D, Seehase S, Richter E, et al. Mycobacteria infect different cell types in the human lung and cause species dependent cellular changes in infected cells. BMC Pulm Med. 2016:16. doi:10.1186/s12890-016-0185-5.26801409
   PubMed Web of Science ®Google Scholar
• Divangahi M, Mostowy S, Coulombe F, et al. NOD2-deficient mice have impaired resistance to mycobacterium tuberculosis infection through defective innate and adaptive immunity. J Immunol. 2008;181(10):7157–7165. doi:10.4049/jimmunol.181.10.715718981137
   PubMed Web of Science ®Google Scholar
• Flannagan RS, Cosío G, Grinstein S. Antimicrobial mechanisms of phagocytes and bacterial evasion strategies. Nat Rev Microbiol. 2009;7(5):355–366. doi:10.1038/nrmicro212819369951
   PubMed Web of Science ®Google Scholar
• Philips JA, Ernst JD. Tuberculosis pathogenesis and Immunity. Annu Rev Pathol Mech Dis. 2012;7(1):353–384. doi:10.1146/annurev-pathol-011811-132458
   PubMedGoogle Scholar
• Schnettger L, Rodgers A, Repnik U, et al. A Rab20-dependent membrane trafficking pathway controls M. tuberculosis replication by regulating phagosome spaciousness and integrity. Cell Host Microbe. 2017;21(5):619–628.e5. doi:10.1021/es103418828494243
   PubMed Web of Science ®Google Scholar
• Tăbăran A-F, Cornel C. Macrophages targeted drug delivery as a key therapy in infectious disease. Biotechnol Mol Biol Nanomedicine. 2014;2:1.
   Google Scholar
• Sturgill-Koszycki S, Schlesinger PH, Chakraborty P, et al. Lack of acidification in Mycobacterium phagosomes produced by exclusion of the vesicular proton-ATPase. Science. 1994;263(5147):678–681. doi:10.1126/science.83032778303277
   PubMed Web of Science ®Google Scholar
• Stanley LR, Vinay K, Abul K, Ramzi S, Nelson F. Robbins & Cotran Pathologic Basis of Disease. Saunders/Elsevier; 2010.
   Google Scholar
• Ferrari G, Langen H, Naito M, Pieters J. A coat protein on phagosomes involved in the intracellular survival of mycobacteria. Cell. 1999;97(4):435–447. doi:10.1016/S0092-8674(00)80754-010338208
   PubMed Web of Science ®Google Scholar
• Hmama Z, Sendide K, Talal A, Garcia R, Dobos K, Reiner NE. Quantitative analysis of phagolysosome fusion in intact cells: inhibition by mycobacterial lipoarabinomannan and rescue by an 1α, 25-dihydroxyvitamin D3–phosphoinositide 3-kinase pathway. J Cell Sci. 2004;117(10):2131–2140. doi:10.1242/jcs.0107215090599
   PubMed Web of Science ®Google Scholar
• Pabst M, Gross J, Brozna J, Goren M. Inhibition of macrophage priming by sulfatide from Mycobacterium tuberculosis. J Immunol. 1988;140(2):634–640.2826597
   PubMed Web of Science ®Google Scholar
• Vergne I, Chua J, Deretic V. Tuberculosis toxin blocking phagosome maturation inhibits a novel Ca2+/calmodulin-PI3K hVPS34 cascade. J Exp Med. 2003;198(4):653–659. doi:10.1084/jem.2003052712925680
   PubMed Web of Science ®Google Scholar
• Clemens DL, Horwitz MA. The Mycobacterium tuberculosis phagosome interacts with early endosomes and is accessible to exogenously administered transferrin. J Exp Med. 1996;184(4):1349–1355. doi:10.1084/jem.184.4.13498879207
   PubMed Web of Science ®Google Scholar
• Lyadova IV, Panteleev AV. Th1 and Th17 cells in tuberculosis: protection, pathology, and biomarkers. Mediators Inflamm. 2015;2015:1–13. doi:10.1155/2015/854507
   Web of Science ®Google Scholar
• Ashenafi S, Aderaye G, Bekele A, et al. Progression of clinical tuberculosis is associated with a Th2 immune response signature in combination with elevated levels of SOCS3. Clin Immunol. 2014;151(2):84–99. doi:10.1016/j.clim.2014.01.01024584041
   PubMed Web of Science ®Google Scholar
• Infante-Duarto C, Kamradt T Thl/Th2 balance in infection.:22.
   Google Scholar
• Mohareer K, Asalla S, Banerjee S. Cell death at the cross roads of host-pathogen interaction in Mycobacterium tuberculosis infection. Tuberculosis. 2018;113:99–121. doi:10.1016/j.tube.2018.09.00730514519
   PubMed Web of Science ®Google Scholar
• Lerner TR, Borel S, Greenwood DJ, et al. Mycobacterium tuberculosis replicates within necrotic human macrophages. J Cell Biol. 2017;216(3):583–594. doi:10.1161/CIRCRESAHA.117.31140128242744
   PubMed Web of Science ®Google Scholar
• Dallenga T, Repnik U, Corleis B, et al. M. tuberculosis-induced necrosis of infected neutrophils promotes bacterial growth following phagocytosis by macrophages. Cell Host Microbe. 2017;22(4):519–530.e3. doi:10.1016/j.chom.2017.09.00329024644
   PubMed Web of Science ®Google Scholar
• Queval CJ, Brosch R, Simeone R. The macrophage: a disputed fortress in the battle against mycobacterium tuberculosis. Front Microbiol. 2017;8. doi:10.3389/fmicb.2017.0228428144237
   PubMedGoogle Scholar
• Shanmugasundaram T, Radhakrishnan M, Gopikrishnan V, Pazhanimurugan R, Balagurunathan R. A study of the bactericidal, anti-biofouling, cytotoxic and antioxidant properties of actinobacterially synthesised silver nanoparticles. Colloids Surf B Biointerfaces. 2013;111:680–687. doi:10.1016/j.colsurfb.2013.06.04523911625
   PubMed Web of Science ®Google Scholar
• Aderibigbe BA. Metal-based nanoparticles for the treatment of infectious diseases. Mol Basel Switz. 2017;22:8. doi:10.3390/molecules22081370
   Google Scholar
• Fathima JB, Pugazhendhi A, Venis R. Synthesis and characterization of ZrO2 nanoparticles-antimicrobial activity and their prospective role in dental care. Microb Pathog. 2017;110:245–251. doi:10.1016/j.micpath.2017.06.03928666841
   PubMed Web of Science ®Google Scholar
• Shanmuganathan R, LewisOscar F, Shanmugam S, et al. Core/shell nanoparticles: synthesis, investigation of antimicrobial potential and photocatalytic degradation of Rhodamine B. J Photochem Photobiol B. 2020;202:111729. doi:10.1016/j.jphotobiol.2019.11172931835161
   PubMed Web of Science ®Google Scholar
• Pugazhendhi A, Kumar SS, Manikandan M, Saravanan M. Photocatalytic properties and antimicrobial efficacy of Fe doped CuO nanoparticles against the pathogenic bacteria and fungi. Microb Pathog. 2018;122:84–89. doi:10.1016/j.micpath.2018.06.01629894807
   PubMed Web of Science ®Google Scholar
• Vasantharaj S, Sathiyavimal S, Senthilkumar P, LewisOscar F, Pugazhendhi A. Biosynthesis of iron oxide nanoparticles using leaf extract of Ruellia tuberosa: antimicrobial properties and their applications in photocatalytic degradation. J Photochem Photobiol B. 2019;192:74–82. doi:10.1016/j.jphotobiol.2018.12.02530685586
   PubMed Web of Science ®Google Scholar
• Reznickova A, Slavikova N, Kolska Z, et al. PEGylated gold nanoparticles: stability, cytotoxicity and antibacterial activity. Colloids Surf Physicochem Eng Asp. 2019;560:26–34. doi:10.1016/j.colsurfa.2018.09.083
   Web of Science ®Google Scholar
• Mocan L, Matea C, Tabaran FA, et al. Selective in vitro photothermal nano-therapy of MRSA infections mediated by IgG conjugated gold nanoparticles. Sci Rep. 2016:6. doi:10.1038/srep39466.28442741
   PubMed Web of Science ®Google Scholar
• Jeyarani S, Vinita NM, Puja P, et al. Biomimetic gold nanoparticles for its cytotoxicity and biocompatibility evidenced by fluorescence-based assays in cancer (MDA-MB-231) and non-cancerous (HEK-293) cells. J Photochem Photobiol B. 2020;202:111715. doi:10.1016/j.jphotobiol.2019.11171531790882
   PubMed Web of Science ®Google Scholar
• Chellapandian C, Ramkumar B, Puja P, Shanmuganathan R, Pugazhendhi A, Kumar P. Gold nanoparticles using red seaweed Gracilaria verrucosa: green synthesis, characterization and biocompatibility studies. Process Biochem. 2019;80:58–63. doi:10.1016/j.procbio.2019.02.009
   Web of Science ®Google Scholar
• Pugazhendhi A, Prabhu R, Muruganantham K, Shanmuganathan R, Natarajan S. Anticancer, antimicrobial and photocatalytic activities of green synthesized magnesium oxide nanoparticles (MgONPs) using aqueous extract of Sargassum wightii. J Photochem Photobiol B. 2019;190:86–97. doi:10.1016/j.jphotobiol.2018.11.01430504053
   PubMed Web of Science ®Google Scholar
• Hariharan D, Thangamuniyandi P, Jegatha Christy A, et al. Enhanced photocatalysis and anticancer activity of green hydrothermal synthesized Ag@TiO2 nanoparticles. J Photochem Photobiol B. 2020;202:111636. doi:10.1016/j.jphotobiol.2019.11163631739259
   PubMed Web of Science ®Google Scholar
• Hariharan D, Thangamuniyandi P, Selvakumar P, et al. Green approach synthesis of Pd@TiO2 nanoparticles: characterization, visible light active picric acid degradation and anticancer activity. Process Biochem. 2019;87:83–88. doi:10.1016/j.procbio.2019.09.024
   Web of Science ®Google Scholar
• Ramkumar VS, Pugazhendhi A, Gopalakrishnan K, et al. Biofabrication and characterization of silver nanoparticles using aqueous extract of seaweed Enteromorpha compressa and its biomedical properties. Biotechnol Rep. 2017;14:1–7. doi:10.1016/j.btre.2017.02.001
   Google Scholar
• Madhubala V, Pugazhendhi A, Thirunavukarasu K. Cytotoxic and immunomodulatory effects of the low concentration of titanium dioxide nanoparticles (TiO2 NPs) on human cell lines - An in vitro study. Process Biochem. 2019;86:186–195. doi:10.1016/j.procbio.2019.08.004
   Web of Science ®Google Scholar
• Fathima JB, Pugazhendhi A, Oves M, Venis R. Synthesis of eco-friendly copper nanoparticles for augmentation of catalytic degradation of organic dyes. J Mol Liq. 2018;260:1–8. doi:10.1016/j.molliq.2018.03.033
   Web of Science ®Google Scholar
• Vasantharaj S, Sathiyavimal S, Saravanan M, et al. Synthesis of ecofriendly copper oxide nanoparticles for fabrication over textile fabrics: characterization of antibacterial activity and dye degradation potential. J Photochem Photobiol B. 2019;191:143–149. doi:10.1016/j.jphotobiol.2018.12.02630639996
   PubMed Web of Science ®Google Scholar
• Saratale RG, Ghodake GS, Shinde SK, et al. Photocatalytic activity of CuO/Cu(OH)2 nanostructures in the degradation of Reactive Green 19A and textile effluent, phytotoxicity studies and their biogenic properties (antibacterial and anticancer). J Environ Manage. 2018;223:1086–1097. doi:10.1016/j.jenvman.2018.04.07229735295
   PubMed Web of Science ®Google Scholar
• Varadavenkatesan T, Lyubchik E, Pai S, Pugazhendhi A, Vinayagam R, Selvaraj R. Photocatalytic degradation of Rhodamine B by zinc oxide nanoparticles synthesized using the leaf extract of Cyanometra ramiflora. J Photochem Photobiol B. 2019;199:111621. doi:10.1016/j.jphotobiol.2019.11162131610434
   PubMed Web of Science ®Google Scholar
• Shanmuganathan R, Edison TNJI, LewisOscar F, Kumar P, Shanmugam S, Pugazhendhi A. Chitosan nanopolymers: an overview of drug delivery against cancer. Int J Biol Macromol. 2019;130:727–736. doi:10.1016/j.ijbiomac.2019.02.06030771392
   PubMed Web of Science ®Google Scholar
• Sanpui P, Chattopadhyay A, Ghosh SS. Induction of apoptosis in cancer cells at low silver nanoparticle concentrations using chitosan nanocarrier. ACS Appl Mater Interfaces. 2011;3(2):218–228. doi:10.1021/am100840c21280584
   PubMed Web of Science ®Google Scholar
• Suganya M, Gnanamangai BM, Govindasamy C, et al. Mitochondrial dysfunction mediated apoptosis of HT-29 cells through CS-PAC-AgNPs and investigation of genotoxic effects in zebra (Danio rerio) fish model for drug delivery. Saudi J Biol Sci. 2019;26(4):767–776. doi:10.1016/j.sjbs.2019.03.00731049002
   PubMed Web of Science ®Google Scholar
• Russell AD, Hugo WB. 7 Antimicrobial activity and action of silver In: Progress in Medicinal Chemistry. Vol. 31 Elsevier;1994::351–370. doi:10.1016/S0079-6468(08)70024-9
   Google Scholar
• Silva JP, Appelberg R, Gama FM. Antimicrobial peptides as novel anti-tuberculosis therapeutics. Biotechnol Adv. 2016;34(5):924–940. doi:10.1016/j.biotechadv.2016.05.00727235189
   PubMed Web of Science ®Google Scholar
• Khan F, Khan MM, Kim Y-M. Recent progress and future perspectives of antibiofilm drugs immobilized on nanomaterials. Curr Pharm Biotechnol. 2018;19(8):631–643. doi:10.2174/138920101966618082809005230152281
   PubMed Web of Science ®Google Scholar
• Raffi M, Mehrwan S, Bhatti TM, et al. Investigations into the antibacterial behavior of copper nanoparticles against Escherichia coli. Ann Microbiol. 2010;60(1):75–80. doi:10.1007/s13213-010-0015-6
   Web of Science ®Google Scholar
• Pham DTN, Khan F, Phan TTV, et al. Biofilm inhibition, modulation of virulence and motility properties by FeOOH nanoparticle in Pseudomonas aeruginosa. Braz J Microbiol. 2019;50(3):791–805. doi:10.1007/s42770-019-00108-z31250405
   PubMed Web of Science ®Google Scholar
• Khan F, Manivasagan P, Lee J-W, Pham DTN, Oh J, Kim Y-M. Fucoidan-stabilized gold nanoparticle-mediated biofilm inhibition, attenuation of virulence and motility properties in Pseudomonas aeruginosa PAO1. Mar Drugs. 2019;17:4. doi:10.3390/md17040208
   Web of Science ®Google Scholar
• Javaid A, Oloketuyi SF, Khan MM, Khan F. Diversity of bacterial synthesis of silver nanoparticles. BioNanoScience. 2018;8(1):43–59. doi:10.1007/s12668-017-0496-x
   Web of Science ®Google Scholar
• Mocan T, Matea CT, Pop T, et al. Carbon nanotubes as anti-bacterial agents. Cell Mol Life Sci CMLS. 2017;74(19):3467–3479. doi:10.1007/s00018-017-2532-y28536787
   PubMed Web of Science ®Google Scholar
• Khan F, Pham DTN, Oloketuyi SF, Manivasagan P, Oh J, Kim Y-M. Chitosan and their derivatives: antibiofilm drugs against pathogenic bacteria. Colloids Surf B Biointerfaces. 2020;185:110627. doi:10.1016/j.colsurfb.2019.11062731732391
   PubMed Web of Science ®Google Scholar
• Khan F, Manivasagan P, Pham DTN, Oh J, Kim S-K, Kim Y-M. Antibiofilm and antivirulence properties of chitosan-polypyrrole nanocomposites to Pseudomonas aeruginosa. Microb Pathog. 2019;128:363–373. doi:10.1016/j.micpath.2019.01.03330684638
   PubMed Web of Science ®Google Scholar
• Manivasagan P, Khan F, Hoang G, et al. Thiol chitosan-wrapped gold nanoshells for near-infrared laser-induced photothermal destruction of antibiotic-resistant bacteria. Carbohydr Polym. 2019;225:115228. doi:10.1016/j.carbpol.2019.11522831521288
   PubMed Web of Science ®Google Scholar
• Zazo H, Colino CI, Lanao JM. Current applications of nanoparticles in infectious diseases. J Control Release off J Control Release Soc. 2016;224:86–102. doi:10.1016/j.jconrel.2016.01.008
   PubMed Web of Science ®Google Scholar
• Costa-gouveia J, Aínsa JA, Brodin P, Lucía A. How can nanoparticles contribute to antituberculosis therapy? Drug Discov Today. 2017;22(3):600–607. doi:10.1016/j.drudis.2017.01.01128137645
   PubMed Web of Science ®Google Scholar
• Kreytsberg GN, Gracheva IE, Kibrik BS, Golikov IV. Antituberculous effect of silver nanoparticles. J Phys Conf Ser. 2011;291:012030. doi:10.1088/1742-6596/291/1/012030
   Google Scholar
• Song B, Zhang C, Zeng G, Gong J, Chang Y, Jiang Y. Antibacterial properties and mechanism of graphene oxide-silver nanocomposites as bactericidal agents for water disinfection. Arch Biochem Biophys. 2016;604:167–176. doi:10.1016/j.abb.2016.04.01827170600
   PubMed Web of Science ®Google Scholar
• Liu C, Guo J, Yan X, et al. Antimicrobial nanomaterials against biofilms: an alternative strategy. Environ Rev. 2016;25(2):225–244. doi:10.1139/er-2016-0046
   Google Scholar
• Franci G, Falanga A, Galdiero S, et al. Silver nanoparticles as potential antibacterial agents. Mol Basel Switz. 2015;20(5):8856–8874. doi:10.3390/molecules20058856
   Google Scholar
• Dakal TC, Kumar A, Majumdar RS, Yadav V. Mechanistic basis of antimicrobial actions of silver nanoparticles. Front Microbiol. 2016;7:1831. doi:10.3389/fmicb.2016.0183127899918
   PubMed Web of Science ®Google Scholar
• Morones JR, Elechiguerra JL, Camacho A, et al. The bactericidal effect of silver nanoparticles. Nanotechnology. 2005;16(10):2346. doi:10.1088/0957-4484/16/10/05920818017
   PubMed Web of Science ®Google Scholar
• Kumar DA, Palanichamy V, Roopan SM. Green synthesis of silver nanoparticles using Alternanthera dentata leaf extract at room temperature and their antimicrobial activity. Spectrochim Acta A Mol Biomol Spectrosc. 2014;127:168–171. doi:10.1016/j.saa.2014.02.05824632169
   PubMed Web of Science ®Google Scholar
• Jain J, Arora S, Rajwade JM, Omray P, Khandelwal S, Paknikar KM. Silver nanoparticles in therapeutics: development of an antimicrobial gel formulation for topical use. Mol Pharm. 2009;6(5):1388–1401. doi:10.1021/mp900056g19473014
   PubMed Web of Science ®Google Scholar
• Le Ouay B, Stellacci F. Antibacterial activity of silver nanoparticles: a surface science insight. Nano Today. 2015;10(3):339–354. doi:10.1016/j.nantod.2015.04.002
   Web of Science ®Google Scholar
• Huh AJ, Kwon YJ. “Nanoantibiotics”: a new paradigm for treating infectious diseases using nanomaterials in the antibiotics resistant era. J Control Release off J Control Release Soc. 2011;156(2):128–145. doi:10.1016/j.jconrel.2011.07.002
   PubMed Web of Science ®Google Scholar
• Kim JS, Kuk E, Yu KN, et al. Antimicrobial effects of silver nanoparticles. Nanomedicine Nanotechnol Biol Med. 2007;3(1):95–101. doi:10.1016/j.nano.2006.12.001
   PubMed Web of Science ®Google Scholar
• Al-Sharqi A, Apun K, Vincent M, Kanakaraju D, Bilung LM. Enhancement of the antibacterial efficiency of silver nanoparticles against gram-positive and gram-negative bacteria using blue laser light. Int J Photoenergy. doi:10.1155/2019/2528490
   Web of Science ®Google Scholar
• Velayati AA, Farnia P, Ibrahim TA, et al. Differences in cell wall thickness between resistant and nonresistant strains of Mycobacterium tuberculosis: using transmission electron microscopy. Chemotherapy. 2009;55(5):303–307. doi:10.1159/00022642519556787
   PubMed Web of Science ®Google Scholar
• Mai-Prochnow A, Clauson M, Hong J, Murphy AB. Gram positive and Gram negative bacteria differ in their sensitivity to cold plasma. Sci Rep. 2016;6. doi:10.1038/srep3861028442741
   PubMedGoogle Scholar
• Hett EC, Rubin EJ. Bacterial growth and cell division: a mycobacterial perspective. Microbiol Mol Biol Rev MMBR. 2008;72(1):126–156. doi:10.1128/MMBR.00028-0718322037
   PubMed Web of Science ®Google Scholar
• Saravanan M, Barik SK, MubarakAli D, Prakash P, Pugazhendhi A. Synthesis of silver nanoparticles from Bacillus brevis (NCIM 2533) and their antibacterial activity against pathogenic bacteria. Microb Pathog. 2018;116:221–226. doi:10.1016/j.micpath.2018.01.03829407231
   PubMed Web of Science ®Google Scholar
• Seth D, Sarkar A, Mitra D. Nanomedicine to counter syndemic tuberculosis and HIV infection: current knowledge and state of art. Nanosci Nanoeng. 2014;9.
   Google Scholar
• Abdel-Aziz MM, Elella MHA, Mohamed RR. Green synthesis of quaternized chitosan/silver nanocomposites for targeting mycobacterium tuberculosis and lung carcinoma cells (A-549). Int J Biol Macromol. 2019. doi:10/ggdd6n
   Web of Science ®Google Scholar
• El Badawy AM, Silva RG, Morris B, Scheckel KG, Suidan MT, Tolaymat TM. Surface charge-dependent toxicity of silver nanoparticles. Environ Sci Technol. 2011;45(1):283–287. doi:10/cc29h521133412
   PubMed Web of Science ®Google Scholar
• Sondi I, Salopek-Sondi B. Silver nanoparticles as antimicrobial agent: a case study on E. coli as a model for Gram-negative bacteria. J Colloid Interface Sci. 2004;275(1):177–182. doi:10.1016/j.jcis.2004.02.01215158396
   PubMed Web of Science ®Google Scholar
• Cho K-H, Park J-E, Osaka T, Park S-G. The study of antimicrobial activity and preservative effects of nanosilver ingredient. Electrochim Acta. 2005;51(5):956–960. doi:10.1016/j.electacta.2005.04.071
   Web of Science ®Google Scholar
• McQuillan JS, Groenaga Infante H, Stokes E, Shaw AM. Silver nanoparticle enhanced silver ion stress response in Escherichia coli K12. Nanotoxicology. 2012;6(8):857–866. doi:10.3109/17435390.2011.62653222007647
   PubMed Web of Science ®Google Scholar
• Orlov IA, Sankova TP, Babich PS, et al. New silver nanoparticles induce apoptosis-like process in E. coli and interfere with mammalian copper metabolism. Int J Nanomedicine. doi:10.2147/IJN.S117745
   Google Scholar
• Rodgers FG, Tzianabos AO, Elliott TSJ. The effect of antibiotics that inhibit cell-wall, protein, and DNA synthesis on the growth and morphology of Legionella pneumophila. J Med Microbiol. 1990;31(1):37–44. doi:10.1099/00222615-31-1-372296040
   PubMed Web of Science ®Google Scholar
• van der Wal A, Norde W, Zehnder AJB, Lyklema J. Determination of the total charge in the cell walls of Gram-positive bacteria. Colloids Surf B Biointerfaces. 1997;9(1–2):81–100. doi:10.1016/S0927-7765(96)01340-9
   Web of Science ®Google Scholar
• Shaik M, Albalawi G, Khan S, et al. “Miswak” based green synthesis of silver nanoparticles: evaluation and comparison of their microbicidal activities with the chemical synthesis. Molecules. 2016;21(11):1478. doi:10.3390/molecules21111478
   PubMed Web of Science ®Google Scholar
• Ashraf S, Akhtar N, Ghauri M, Rajoka M, Khalid ZM, Hussain I. Polyhexamethylene biguanide functionalized cationic silver nanoparticles for enhanced antimicrobial activity. Nanoscale Res Lett. 2012;7(1):267. doi:10.1186/1556-276X-7-26722625664
   PubMedGoogle Scholar
• Ivask A, ElBadawy A, Kaweeteerawat C, et al. Toxicity mechanisms in escherichia coli vary for silver nanoparticles and differ from ionic silver. ACS Nano. 2014;8(1):374–386. doi:10/f5qqhz24341736
   PubMed Web of Science ®Google Scholar
• Kvítek L, Panáček A, Soukupová J, et al. Effect of surfactants and polymers on stability and antibacterial activity of silver nanoparticles (NPs). J Phys Chem C. 2008;112(15):5825–5834. doi:10.1021/jp711616v
   Web of Science ®Google Scholar
• Yin R, Agrawal T, Khan U, et al. Antimicrobial photodynamic inactivation in nanomedicine: small light strides against bad bugs. Nanomed. 2015;10(15):2379–2404. doi:10.2217/nnm.15.67
   PubMed Web of Science ®Google Scholar
• Yun’an Qing LC, Li R, Liu G, et al. Potential antibacterial mechanism of silver nanoparticles and the optimization of orthopedic implants by advanced modification technologies. Int J Nanomedicine. 2018;13:3311. doi:10.2147/IJN.S16512529892194
   PubMed Web of Science ®Google Scholar
• Bonnet M, Massard C, Veisseire P, Camares O, Awitor KO. Environmental toxicity and antimicrobial efficiency of titanium dioxide nanoparticles in suspension. J Biomater Nanobiotech. 2015;6(3):213–224. doi:10.4236/jbnb.2015.63020
   Google Scholar
• Parikh AN, Gillmor SD, Beers JD, Beardmore KM, Cutts RW, Swanson BI. Characterization of chain molecular assemblies in long-chain, layered silver thiolates: a joint infrared spectroscopy and X-ray diffraction study. J Phys Chem B. 1999;103(15):2850–2861. doi:10.1021/jp983938b
   Web of Science ®Google Scholar
• Dobias J, Bernier-Latmani R. Silver release from silver nanoparticles in natural waters. Environ Sci Technol. 2013;47(9):4140–4146. doi:10.1021/es304023p23517230
   PubMed Web of Science ®Google Scholar
• Park E-J, Yi J, Kim Y, Choi K, Park K. Silver nanoparticles induce cytotoxicity by a Trojan-horse type mechanism. Toxicol in Vitro. 2010;24(3):872–878. doi:10.1016/j.tiv.2009.12.00119969064
   PubMed Web of Science ®Google Scholar
• He D, Miller CJ, Waite TD. Fenton-like zero-valent silver nanoparticle-mediated hydroxyl radical production. J Catal. 2014;317:198–205. doi:10.1016/j.jcat.2014.06.016
   Web of Science ®Google Scholar
• Sisubalan N, Ramkumar VS, Pugazhendhi A, et al. ROS-mediated cytotoxic activity of ZnO and CeO2 nanoparticles synthesized using the Rubia cordifolia L. leaf extract on MG-63 human osteosarcoma cell lines. Environ Sci Pollut Res. 2018;25(11):10482–10492. doi:10.1007/s11356-017-0003-5
   PubMed Web of Science ®Google Scholar
• Knaapen AM, Borm PJA, Albrecht C, Schins RPF. Inhaled particles and lung cancer. Part A: mechanisms. Int J Cancer. 2004;109(6):799–809. doi:10.1002/ijc.1170815027112
   PubMed Web of Science ®Google Scholar
• Samuel MS, Jose S, Selvarajan E, Mathimani T, Pugazhendhi A. Biosynthesized silver nanoparticles using Bacillus amyloliquefaciens; application for cytotoxicity effect on A549 cell line and photocatalytic degradation of p-nitrophenol. J Photochem Photobiol B. 2020;202:111642. doi:10.1016/j.jphotobiol.2019.11164231734434
   PubMed Web of Science ®Google Scholar
• Speight JG, editor. Redox Transformations In: Reaction Mechanisms in Environmental Engineering. Elsevier; 2018:231–267. doi:10.1016/B978-0-12-804422-3.00007-9
   Google Scholar
• Forrester SJ, Kikuchi DS, Hernandes MS, Xu Q, Griendling KK. Reactive oxygen species in metabolic and inflammatory signaling. Circ Res. 2018;122(6):877–902. doi:10.1161/CIRCRESAHA.117.31140129700084
   PubMed Web of Science ®Google Scholar
• Zielinska E, Tukaj C, Radomski MW, Inkielewicz-stepniak I. Molecular mechanism of silver nanoparticles-induced human osteoblast cell death: protective effect of inducible nitric oxide synthase inhibitor. PLoS One. 2016;11(10):e0164137. doi:10/f9rvdx27716791
   PubMed Web of Science ®Google Scholar
• Bressan E, Ferroni L, Gardin C, et al. Silver nanoparticles and mitochondrial interaction. Int J Dent. 2013;2013:1–8. doi:10.1155/2013/312747
   Google Scholar
• Maurer LL, Meyer JN. A systematic review of evidence for silver nanoparticle-induced mitochondrial toxicity. Environ Sci Nano. 2016;3(2):311–322. doi:10.1039/C5EN00187K
   Web of Science ®Google Scholar
• Kim S, Choi JE, Choi J, et al. Oxidative stress-dependent toxicity of silver nanoparticles in human hepatoma cells. Toxicol in Vitro. 2009;23(6):1076–1084. doi:10.1016/j.tiv.2009.06.00119508889
   PubMed Web of Science ®Google Scholar
• Miyayama T, Matsuoka M. Involvement of lysosomal dysfunction in silver nanoparticle-induced cellular damage in A549 human lung alveolar epithelial cells. J Occup Med Toxicol. 2016;11(1):1. doi:10.1186/s12995-016-0090-026759602
   PubMedGoogle Scholar
• Park MVDZ, Neigh AM, Vermeulen JP, et al. The effect of particle size on the cytotoxicity, inflammation, developmental toxicity and genotoxicity of silver nanoparticles. Biomaterials. 2011;32(36):9810–9817. doi:10.1016/j.biomaterials.2011.08.08521944826
   PubMed Web of Science ®Google Scholar
• Singh R, Nawale L, Arkile M, et al. Phytogenic silver, gold, and bimetallic nanoparticles as novel antitubercular agents. Int J Nanomedicine. 2016;11:1889.27217751
   PubMed Web of Science ®Google Scholar
• Xiu Z, Zhang Q, Puppala HL, Colvin VL, Alvarez PJJ. Negligible particle-specific antibacterial activity of silver nanoparticles. Nano Lett. 2012;12(8):4271–4275. doi:10.1021/nl301934w22765771
   PubMed Web of Science ®Google Scholar
• Behra R, Sigg L, Clift MJD, et al. Bioavailability of silver nanoparticles and ions: from a chemical and biochemical perspective. J R Soc Interface. 2013;10:87. doi:10.1098/rsif.2013.0396
   Web of Science ®Google Scholar
• Saratale RG, Karuppusamy I, Saratale GD, et al. A comprehensive review on green nanomaterials using biological systems: recent perception and their future applications. Colloids Surf B Biointerfaces. 2018;170:20–35. doi:10.1016/j.colsurfb.2018.05.04529860217
   PubMed Web of Science ®Google Scholar
• Saratale RG, Saratale GD, Shin HS, et al. New insights on the green synthesis of metallic nanoparticles using plant and waste biomaterials: current knowledge, their agricultural and environmental applications. Environ Sci Pollut Res. 2018;25(11):10164–10183. doi:10.1007/s11356-017-9912-6
   PubMed Web of Science ®Google Scholar
• Kote JR, Kadam AS, Patil SS, Mane RS. Green functionalized silver nanoparticles with significantly enhanced antimycobactericidal and cytotoxicity performances of asparagus racemosus Linn. Int J New Technol Sci. 2016;3(2):15.
   Google Scholar
• Roy A, Bulut O, Some S, Mandal AK, Yilmaz MD. Green synthesis of silver nanoparticles: biomolecule-nanoparticle organizations targeting antimicrobial activity. RSC Adv. 2019;9(5):2673–2702. doi:10.1039/C8RA08982E
   PubMed Web of Science ®Google Scholar
• Kerry RG, Gouda S, Sil B, et al. Cure of tuberculosis using nanotechnology: an overview. J Microbiol. 2018;56(5):287–299. doi:10.1007/s12275-018-7414-y29721825
   PubMed Web of Science ®Google Scholar
• Arokiyaraj S, Arasu MV, Vincent S, et al. Rapid green synthesis of silver nanoparticles from Chrysanthemum indicum L and its antibacterial and cytotoxic effects: an in vitro study. Int J Nanomedicine. doi:10.2147/IJN.S53546
   Web of Science ®Google Scholar
• Ahmed S, Ahmad M, Swami BL, Ikram S. A review on plants extract mediated synthesis of silver nanoparticles for antimicrobial applications: a green expertise. J Adv Res. 2016;7(1):17–28. doi:10.1016/j.jare.2015.02.00726843966
   PubMed Web of Science ®Google Scholar
• Shaik M, Khan M, Kuniyil M, et al. Plant-extract-assisted green synthesis of silver nanoparticles using origanum vulgare L. Extract and their microbicidal activities. Sustainability. 2018;10(4):913. doi:10.3390/su10040913
   Web of Science ®Google Scholar
• Pugazhendhi A, Prabakar D, Jacob JM, Karuppusamy I, Saratale RG. Synthesis and characterization of silver nanoparticles using Gelidium amansii and its antimicrobial property against various pathogenic bacteria. Microb Pathog. 2018;114:41–45. doi:10.1016/j.micpath.2017.11.01329146498
   PubMed Web of Science ®Google Scholar
• Oves M, Aslam M, Rauf MA, et al. Antimicrobial and anticancer activities of silver nanoparticles synthesized from the root hair extract of Phoenix dactylifera. Mater Sci Eng C. 2018;89:429–443. doi:10.1016/j.msec.2018.03.035
   PubMed Web of Science ®Google Scholar
• Singh R, Nawale LU, Arkile M, et al. Chemical and biological metal nanoparticles as antimycobacterial agents: a comparative study. Int J Antimicrob Agents. 2015;46(2):183–188. doi:10.1016/j.ijantimicag.2015.03.01426009020
   PubMed Web of Science ®Google Scholar
• Rónavári A, Kovács D, Igaz N, et al. Biological activity of green-synthesized silver nanoparticles depends on the applied natural extracts: a comprehensive study. Int J Nanomedicine. 2017;12:871–883. doi:10.2147/IJN.S12284228184158
   PubMed Web of Science ®Google Scholar
• Rai M, Ingle AP, Pandit R, et al. Broadening the spectrum of small-molecule antibacterials by metallic nanoparticles to overcome microbial resistance. Int J Pharm. 2017;532(1):139–148. doi:10.1016/j.ijpharm.2017.08.12728870767
   PubMedGoogle Scholar
• Baptista PV, McCusker MP, Carvalho A, et al. Nano-strategies to fight multidrug resistant bacteria—“a battle of the titans. Front Microbiol. 2018;9:1441. doi:10.3389/fmicb.2018.0144130013539
   PubMed Web of Science ®Google Scholar
• Djafari J, Marinho C, Santos T, et al. New synthesis of gold- and silver-based nano-tetracycline composites. ChemistryOpen. 2016;5(3):206–212. doi:10.1002/open.20160001627957408
   PubMed Web of Science ®Google Scholar
• Deng H, McShan D, Zhang Y, et al. Mechanistic study of the synergistic antibacterial activity of combined silver nanoparticles and common antibiotics. Environ Sci Technol. 2016;50(16):8840–8848. doi:10.1021/acs.est.6b0099827390928
   PubMed Web of Science ®Google Scholar
• Birla SS, Tiwari VV, Gade AK, Ingle AP, Yadav AP, Rai MK. Fabrication of silver nanoparticles by Phoma glomerata and its combined effect against Escherichia coli, Pseudomonas aeruginosa and Staphylococcus aureus. Lett Appl Microbiol. 2009;48(2):173–179. doi:10.1111/j.1472-765X.2008.02510.x19141039
   PubMed Web of Science ®Google Scholar
• Brown AN, Smith K, Samuels TA, Lu J, Obare SO, Scott ME. Nanoparticles functionalized with ampicillin destroy multiple-antibiotic-resistant isolates of pseudomonas aeruginosa and enterobacter aerogenes and methicillin-resistant Staphylococcus aureus. Appl Environ Microbiol. 2012;78(8):2768–2774. doi:10.1128/AEM.06513-1122286985
   PubMed Web of Science ®Google Scholar
• Saratale GD, Saratale RG, Benelli G, et al. Anti-diabetic potential of silver nanoparticles synthesized with argyreia nervosa leaf extract high synergistic antibacterial activity with standard antibiotics against foodborne bacteria. J Clust Sci. 2017;28(3):1709–1727. doi:10.1007/s10876-017-1179-z
   Web of Science ®Google Scholar
• Shanmuganathan R, MubarakAli D, Prabakar D, et al. An enhancement of antimicrobial efficacy of biogenic and ceftriaxone-conjugated silver nanoparticles: green approach. Environ Sci Pollut Res. 2018;25(11):10362–10370. doi:10.1007/s11356-017-9367-9
   PubMed Web of Science ®Google Scholar
• Hwang I-S, Hwang JH, Choi H, Kim K-J, Lee DG. Synergistic effects between silver nanoparticles and antibiotics and the mechanisms involved. J Med Microbiol. 2012;61(Pt_12):1719–1726. doi:10.1099/jmm.0.047100-022956753
   PubMed Web of Science ®Google Scholar
• Farooq U, Ahmad T, Khan A, et al. Rifampicin conjugated silver nanoparticles: a new arena for development of antibiofilm potential against methicillin resistant Staphylococcus aureus and Klebsiella pneumoniae. Int J Nanomedicine. 2019;14:3983–3993. doi:10.2147/IJN.S19819431213810
   PubMed Web of Science ®Google Scholar
• Li P, Li J, Wu C, Wu Q, Li J. Synergistic antibacterial effects of β-lactam antibiotic combined with silver nanoparticles. Nanotechnology. 2005;16(9):1912–1917. doi:10.1088/0957-4484/16/9/082
   Web of Science ®Google Scholar
• Arakha M, Jha S. Effects of photocatalytic nanoparticle interfaces on biological membranes and biomacromolecules. 2017. doi:10/ggdp7k
   Google Scholar
• Nasiruddin M, Neyaz M, Das S. Nanotechnology-based approach in tuberculosis treatment. Tuberc Res Treat. 2017;2017. doi:10.1155/2017/4920209.
   PubMedGoogle Scholar
• Singh R, Nawale L, Arkile M, et al. Phytogenic silver, gold, and bimetallic nanoparticles as novel antitubercular agents. Int J Nanomedicine. 2016;11:1889–1897. doi:10.2147/IJN.S10248827217751
   PubMed Web of Science ®Google Scholar
• Song HY, Ko KK, Oh IH, Lee BT. Fabrication of silver nanoparticles and their antimicrobial mechanisms. Eur Cell Mater. 2006;11(suppl 1):58.
   Google Scholar
• Jaryal N, Kaur H. Plumbago auriculata leaf extract-mediated AgNPs and its activities as antioxidant, anti-TB and dye degrading agents. J Biomater Sci Polym Ed. 2017;28(16):1847–1858. doi:10.1080/09205063.2017.135467328697688
   PubMed Web of Science ®Google Scholar
• Paarakh PM. Anti-tubercular activity of silver nanoparticle synthesized from the fruits of coriandrum sativum linn. World J Pharm Pharm Sci. 2017;1720–1727. doi:10/ggdkzz
   Google Scholar
• Raja A, Salique SM, Gajalakshmi P, James A. Antibacterial and hemolytic activity of green silver nanoparticles from Catharanthus roseus. Int J Pharm Sci Nanotechnol. 2016;9(1):7.
   Google Scholar
• Kote JR, Mulani RM, Kadam AS, Solankar BM. Anti-Mycobacterial Activity of Nanoparticles from Psidium Guajava L. 2014:5.
   Google Scholar
• Daniel SCGK, Banu BN, Harshiny M, et al. Ipomea carnea -based silver nanoparticle synthesis for antibacterial activity against selected human pathogens. J Exp Nanosci. 2014;9(2):197–209. doi:10.1080/17458080.2011.654274
   Web of Science ®Google Scholar
• Banu A. Biosynthesis of monodispersed silver nanoparticles and their activity against Mycobacterium tuberculosis. J Nanomedicine Biotherapeutic Discov. 2013;03:01. doi:10.4172/2155-983X.1000110
   Google Scholar
• Agarwal P, Mehta A, Kachhwaha S, Kothari SL. Green synthesis of silver nanoparticles and their activity against Mycobacterium tuberculosis. Adv Sci Eng Med. 2013;5(7):709–714. doi:10.1166/asem.2013.1307
   Google Scholar
• Heidary M, Zaker Bostanabad S, Amini SM, et al. The anti-mycobacterial activity of Ag, ZnO, And Ag- ZnO nanoparticles against MDR- and XDR-Mycobacterium tuberculosis. Infect Drug Resist. 2019;12:3425–3435. doi:10.2147/IDR.S22140831807033
   PubMed Web of Science ®Google Scholar
• Ellis T, Chiappi M, García-trenco A, et al. Multimetallic microparticles increase the potency of rifampicin against intracellular Mycobacterium tuberculosis. ACS Nano. 2018;12(6):5228–5240. doi:10.1021/acsnano.7b0826429767993
   PubMed Web of Science ®Google Scholar
• Jafari A, Mosavari N, Movahedzadeh F, et al. Bactericidal impact of Ag, ZnO and mixed AgZnO colloidal nanoparticles on HRv Mycobacterium tuberculosis phagocytized by THP-1 cell lines. Microb Pathog. 2017;110:335–344. doi:10.1016/j.micpath.2017.07.01028710015
   PubMed Web of Science ®Google Scholar
• Jena P, Mohanty S, Mallick R, Jacob B, Sonawane A. Toxicity and antibacterial assessment of chitosancoated silver nanoparticles on human pathogens and macrophage cells. Int J Nanomedicine. 2012;7:1805. doi:10.2147/IJN.S3063122619529
   PubMed Web of Science ®Google Scholar
• Selim A, Elhaig MM, Taha SA, Nasr EA. Antibacterial activity of silver nanoparticles against field and reference strains of Mycobacterium tuberculosis, Mycobacterium bovis and multiple-drug-resistant tuberculosis strains. Rev Sci Tech OIE. 2018;37(3):823–830. doi:10.20506/rst.37.3.2888
   PubMed Web of Science ®Google Scholar
• Sivaraj A, Kumar V, Sunder R, Parthasarathy K, Kasivelu G. Commercial yeast extracts mediated green synthesis of silver chloride nanoparticles and their anti-mycobacterial activity. J Clust Sci. 2019. doi:10/ggdgtw
   Web of Science ®Google Scholar
• Kim J, Pitts B, Stewart PS, Camper A, Yoon J. Comparison of the antimicrobial effects of chlorine, silver ion, and tobramycin on biofilm. Antimicrob Agents Chemother. 2008;52(4):1446–1453. doi:10.1128/AAC.00054-0718195062
   PubMed Web of Science ®Google Scholar
• Patel S. Biogenic silver nanoparticles as potential agent against mycobacterium tuberculosis. Int J Res Appl Sci Eng Technol. 2018;6(1):505–511. doi:10.22214/ijraset.2018.1075
   Google Scholar
• Seth D, Choudhury SR, Pradhan S, et al. Nature-inspired novel drug design paradigm using nanosilver: efficacy on multi-drug-resistant clinical isolates of tuberculosis. Curr Microbiol. 2011;62(3):715–726. doi:10.1007/s00284-010-9770-720936471
   PubMed Web of Science ®Google Scholar
• Punjabi K, Mehta S, Chavan R, Chitalia V, Deogharkar D, Deshpande S. Efficiency of biosynthesized silver and zinc nanoparticles against multi-drug resistant pathogens. Front Microbiol. 2018;9. doi:10/gfdvdk29387050
   PubMed Web of Science ®Google Scholar
• Sun F, Oh S, Kim J, et al. Enhanced internalization of macromolecular drugs into mycobacterium smegmatis with the assistance of silver nanoparticles. J Microbiol Biotechnol. 2017;27(8):1483–1490. doi:10.4014/jmb.1612.1204128595381
   PubMed Web of Science ®Google Scholar
• Padmaa MP. Green synthesis of silver nanoparticles using fruits of coriandrum sativum linn and its antioxidant activity. J Nat Prod Resour. 2015;1(1):19–22.
   Google Scholar
• Donnellan S, Tran L, Johnston H, McLuckie J, Stevenson K, Stone V. A rapid screening assay for identifying mycobacteria targeted nanoparticle antibiotics. Nanotoxicology. 2016;10(6):761–769. doi:10.3109/17435390.2015.112446826618564
   PubMed Web of Science ®Google Scholar
• Jafari AR, Mosavi T, Mosavari N, et al. Mixed metal oxide nanoparticles inhibit growth of Mycobacterium tuberculosis into THP-1 cells. Int J Mycobacteriology. 2016;5:S181–S183. doi:10.1016/j.ijmyco.2016.09.011
   PubMedGoogle Scholar
• Islam MS, Larimer C, Ojha A, Nettleship I. Antimycobacterial efficacy of silver nanoparticles as deposited on porous membrane filters. Mater Sci Eng C. 2013;33(8):4575–4581. doi:10.1016/j.msec.2013.07.013
   PubMed Web of Science ®Google Scholar
• Mohanty S, Mishra S, Jena P, Jacob B, Sarkar B, Sonawane A. An investigation on the antibacterial, cytotoxic, and antibiofilm efficacy of starch-stabilized silver nanoparticles. Nanomedicine Nanotechnol Biol Med. 2012;8(6):916–924. doi:10.1016/j.nano.2011.11.007
   PubMed Web of Science ®Google Scholar
• Zhou Y, Kong Y, Kundu S, Cirillo JD, Liang H. Antibacterial activities of gold and silver nanoparticles against Escherichia coli and bacillus Calmette-Guérin. J Nanobiotechnology. 2012;10(1):19. doi:10.1186/1477-3155-10-1922559747
   PubMedGoogle Scholar
• Martinez-Gutierrez F, Olive PL, Banuelos A, et al. Synthesis, characterization, and evaluation of antimicrobial and cytotoxic effect of silver and titanium nanoparticles. Nanomedicine Nanotechnol Biol Med. 2010;6(5):681–688. doi:10.1016/j.nano.2010.02.001
   PubMed Web of Science ®Google Scholar
• Varghese MV, Dhumal RS, Patil SS, Paradkar AR, Khanna PK. Synthesis and in-vitro antimycobacterial studies of cysteine capped silver nano-particles. Synth React Inorg Met-Org Nano-Met Chem. 2009;39(9):554–558. doi:10.1080/15533170903327869
   Web of Science ®Google Scholar
• Uraskulova BB, Gyusan AO. The clinical and bacteriological study of the effectiveness of the application of silver nanoparticle for the treatment of tuberculosis. Vestn Otorinolaringol. 2017;82(3):54–57. doi:10.17116/otorino201782354-5728631683
   PubMedGoogle Scholar
• Gmoshinski IV, Shumakova AA, Shipelin VA, Maltsev G, Khotimchenko SA. Influence of orally introduced silver nanoparticles on content of essential and toxic trace elements in organism. Nanotechnologies Russ. 2016;11(9–10):646–652. doi:10.1134/S1995078016050074
   Google Scholar
• Zakharov AV, Khokhlov AL, Kibrik BS. Effectiveness of combination of isoniazid and silver nanoparticles in the treatment of experimental tuberculosis. Tuberc Lung Dis. 2017;95(6):51–58. doi:10.21292/2075-1230-2017-95-6-51-58
   Google Scholar
• Zakharov AV, Khokhlov A. The results of experimental studies of the use of silver nanoparticles in tuberculosis drug-resistant pathogen. Med News North Cauc. 2019;14:1. doi:10/ggdjnk
   Google Scholar
• Pugazhendhi A, Edison TNJI, Karuppusamy I, Kathirvel B. Inorganic nanoparticles: a potential cancer therapy for human welfare. Int J Pharm. 2018;539(1):104–111. doi:10.1016/j.ijpharm.2018.01.03429366941
   PubMedGoogle Scholar
• Srinivasan M, Venkatesan M, Arumugam V, et al. Green synthesis and characterization of titanium dioxide nanoparticles (TiO2 NPs) using Sesbania grandiflora and evaluation of toxicity in zebrafish embryos. Process Biochem. 2019;80:197–202. doi:10.1016/j.procbio.2019.02.010
   Web of Science ®Google Scholar
• Vazquez-Muñoz R, Borrego B, Juárez-moreno K, et al. Toxicity of silver nanoparticles in biological systems: does the complexity of biological systems matter? Toxicol Lett. 2017;276:11–20. doi:10.1016/j.toxlet.2017.05.00728483428
   PubMed Web of Science ®Google Scholar
• Tarannum N, Divya K, Gautam Y. Facile green synthesis and applications of silver nanoparticles: a state-of-the-art review. RSC Adv. 2019;9(60):34926–34948. doi:10.1039/C9RA04164H
   PubMed Web of Science ®Google Scholar
• Dey Bhowmik A, Bandyopadhyay A, Chattopadhyay A. Cytotoxic and mutagenic effects of green silver nanoparticles in cancer and normal cells: a brief review. The Nucleus. 2019;62(3):277–285. doi:10.1007/s13237-019-00293-0
   Web of Science ®Google Scholar
• Saravanan M, Arokiyaraj S, Lakshmi T, Pugazhendhi A. Synthesis of silver nanoparticles from Phenerochaete chrysosporium (MTCC-787) and their antibacterial activity against human pathogenic bacteria. Microb Pathog. 2018;117:68–72. doi:10.1016/j.micpath.2018.02.00829427709
   PubMed Web of Science ®Google Scholar
• Yuan D, He H, Wu Y, Fan J, Cao Y. Physiologically based pharmacokinetic modeling of nanoparticles. J Pharm Sci. 2019;108(1):58–72. doi:10.1016/j.xphs.2018.10.03730385282
   PubMed Web of Science ®Google Scholar
• Ehlers S, Schaible UE. The granuloma in tuberculosis: dynamics of a host–pathogen collusion. Front Immunol. 2013;3. doi:10.3389/fimmu.2012.00411.
   PubMed Web of Science ®Google Scholar
• Sarkar S, Leo BF, Carranza C, et al. Modulation of human macrophage responses to mycobacterium tuberculosis by silver nanoparticles of different size and surface modification. PLoS One. 2015;10(11):e0143077. doi:10.1371/journal.pone.014307726580078
   PubMed Web of Science ®Google Scholar
• De Jong WH, Van Der Ven LTM, Sleijffers A, et al. Systemic and immunotoxicity of silver nanoparticles in an intravenous 28 days repeated dose toxicity study in rats. Biomaterials. 2013;34(33):8333–8343. doi:10.1016/j.biomaterials.2013.06.04823886731
   PubMed Web of Science ®Google Scholar
• Müller L, Steiner SK, Rodriguez-lorenzo L, Petri-fink A, Rothen-rutishauser B, Latzin P. Exposure to silver nanoparticles affects viability and function of natural killer cells, mostly via the release of ions. Cell Biol Toxicol. 2018;34(3):167–176. doi:10.1007/s10565-017-9403-z28721573
   PubMed Web of Science ®Google Scholar
• Alsaleh NB, Minarchick VC, Mendoza RP, Sharma B, Podila R, Brown JM. Silver nanoparticle immunomodulatory potential in absence of direct cytotoxicity in RAW 264.7 macrophages and MPRO 2.1 neutrophils. J Immunotoxicol. 2019;16(1):63–73. doi:10.1080/1547691X.2019.158892831282784
   PubMed Web of Science ®Google Scholar
• Yen H, Hsu S, Tsai C. Cytotoxicity and immunological response of gold and silver nanoparticles of different sizes. Small. 2009;5(13):1553–1561. doi:10.1002/smll.20090012619326357
   PubMed Web of Science ®Google Scholar
• Li T, Albee B, Alemayehu M, et al. Comparative toxicity study of Ag, Au, and Ag–Au bimetallic nanoparticles on Daphnia magna. Anal Bioanal Chem. 2010;398(2):689–700. doi:10.1007/s00216-010-3915-120577719
   PubMed Web of Science ®Google Scholar
• Suganthy N, Sri Ramkumar V, Pugazhendhi A, Benelli G, Archunan G. Biogenic synthesis of gold nanoparticles from Terminalia arjuna bark extract: assessment of safety aspects and neuroprotective potential via antioxidant, anticholinesterase, and antiamyloidogenic effects. Environ Sci Pollut Res. 2018;25(11):10418–10433. doi:10.1007/s11356-017-9789-4
   PubMed Web of Science ®Google Scholar
• Larimer C, Islam MS, Ojha A, Nettleship I. Mutation of environmental mycobacteria to resist silver nanoparticles also confers resistance to a common antibiotic. BioMetals. 2014;27(4):695–702. doi:10.1007/s10534-014-9761-424989695
   PubMed Web of Science ®Google Scholar
• Panáček A, Kvítek L, Smékalová M, et al. Bacterial resistance to silver nanoparticles and how to overcome it. Nat Nanotechnol. 2018;13(1):65–71. doi:10.1038/s41565-017-0013-y29203912
   PubMed Web of Science ®Google Scholar
• Muller M. Bacterial silver resistance gained by cooperative interspecies redox behavior. Antimicrob Agents Chemother. 2018;62:8. doi:10.1128/AAC.00672-18
   Web of Science ®Google Scholar
• Silver S. Bacterial silver resistance: molecular biology and uses and misuses of silver compounds. FEMS Microbiol Rev. 2003;27(2–3):341–353. doi:10.1016/S0168-6445(03)00047-012829274
   PubMed Web of Science ®Google Scholar
• Mijnendonckx K, Ali MM, Provoost A, et al. Spontaneous mutation in the AgrRS two-component regulatory system of Cupriavidus metallidurans results in enhanced silver resistance. Metallomics. 2019;11(11):1912–1924. doi:10.1039/C9MT00123A31609372
   PubMed Web of Science ®Google Scholar
• McDonnell G, Russell AD. Antiseptics and disinfectants: activity, action, and resistance. Clin Microbiol Rev. 1999;12(1):147–179. doi:10.1128/CMR.12.1.1479880479
   PubMed Web of Science ®Google Scholar
• Percival SL, Bowler PG, Russell D. Bacterial resistance to silver in wound care. J Hosp Infect. 2005;60(1):1–7. doi:10.1016/j.jhin.2004.11.01415823649
   PubMed Web of Science ®Google Scholar
• Woods EJ, Cochrane CA, Percival SL. Prevalence of silver resistance genes in bacteria isolated from human and horse wounds. Vet Microbiol. 2009;138(3–4):325–329. doi:10.1016/j.vetmic.2009.03.02319362435
   PubMed Web of Science ®Google Scholar
• Loh JV, Percival SL, Woods EJ, Williams NJ, Cochrane CA. Silver resistance in MRSA isolated from wound and nasal sources in humans and animals. Int Wound J. 2009;6(1):32–38. doi:10.1111/j.1742-481X.2008.00563.x19291113
   PubMed Web of Science ®Google Scholar
• Finley PJ, Norton R, Austin C, Mitchell A, Zank S, Durham P. Unprecedented silver resistance in clinically isolated enterobacteriaceae: major implications for burn and wound management. Antimicrob Agents Chemother. 2015;59(8):4734–4741. doi:10.1128/AAC.00026-1526014954
   PubMed Web of Science ®Google Scholar
• Percival SL, Woods E, Nutekpor M, Bowler P, Radford A, Cochrane C. Prevalence of silver resistance in bacteria isolated from diabetic foot ulcers and efficacy of silver-containing wound dressings. Ostomy Wound Manage. 2008;54(3):30–40.
   PubMedGoogle Scholar
• Davis IJ, Richards H, Mullany P. Isolation of silver- and antibiotic-resistant Enterobacter cloacae from teeth. Oral Microbiol Immunol. 2005;20(3):191–194. doi:10.1111/j.1399-302X.2005.00218.x15836522
   PubMedGoogle Scholar
• Summers AO, Wireman J, Vimy MJ, et al. Mercury released from dental “silver” fillings provokes an increase in mercury- and antibiotic-resistant bacteria in oral and intestinal floras of primates. Antimicrob Agents Chemother. 1993;37(4):825–834. doi:10.1128/AAC.37.4.8258280208
   PubMed Web of Science ®Google Scholar
• Haefeli C, Franklin C, Hardy K. Plasmid-determined silver resistance in Pseudomonas stutzeri isolated from a silver mine. J Bacteriol. 1984;158(1):389–392. doi:10.1128/JB.158.1.389-392.19846715284
   PubMed Web of Science ®Google Scholar
• Hanczvikkel A, Víg A, Tóth Á. Survival capability of healthcare-associated, multidrug-resistant bacteria on untreated and on antimicrobial textiles. J Ind Text. 2019;48(7):1113–1135. doi:10.1177/1528083718754901
   Web of Science ®Google Scholar
• Chapman JS. Disinfectant resistance mechanisms, cross-resistance, and co-resistance. Int Biodeterior Biodegrad. 2003;51(4):271–276. doi:10.1016/S0964-8305(03)00044-1
   Web of Science ®Google Scholar
• Rodgers MR, Blackstone BJ, Reyes AL, Covert TC. Colonisation of point of use water filters by silver resistant non-tuberculous mycobacteria. J Clin Pathol. 1999;52(8):629. doi:10.1136/jcp.52.8.629a
   PubMed Web of Science ®Google Scholar
• Li XZ, Nikaido H, Williams KE. Silver-resistant mutants of Escherichia coli display active efflux of Ag+ and are deficient in porins. J Bacteriol. 1997;179(19):6127–6132. doi:10.1128/JB.179.19.6127-6132.19979324262
   PubMed Web of Science ®Google Scholar
• Gupta A, Matsui K, Lo J-F, Silver S. Molecular basis for resistance to silver cations in Salmonella. Nat Med. 1999;5(2):183–188. doi:10.1038/55459930866
   PubMed Web of Science ®Google Scholar
• Li W, Zhang H, Assaraf YG, et al. Overcoming ABC transporter-mediated multidrug resistance: molecular mechanisms and novel therapeutic drug strategies. Drug Resist Updat Rev Comment Antimicrob Anticancer Chemother. 2016;27:14–29. doi:10.1016/j.drup.2016.05.001
   Google Scholar